Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.50 |
| ▸ | PPARD | Q03181 | 5/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20595190 | 0.98 | PPARA (0.49) | PPARAPPARDMRGPRX4FFAR4FFAR1 | |
| SCHEMBL8959081 | 0.91 | PPARA (0.51) | PPARAPPARDMRGPRX4FFAR4FFAR1 | |
| SCHEMBL13545909 | 0.84 | PPARA (0.59) | PPARAPPARDMRGPRX4FFAR4FFAR1 | |
| SCHEMBL4458527 | 0.84 | PPARA (0.53) | PPARAPPARDMRGPRX4FFAR4FFAR1 | |
| SCHEMBL10800881 | 0.84 | PPARA (0.50) | PPARAPPARDMRGPRX4FFAR4FFAR1 | |
| SCHEMBL4465407 | 0.84 | PPARA (0.50) | PPARAPPARDMRGPRX4FFAR4FFAR1 | |
| Hydrochloric Acid SCHEMBL3146300 | 0.84 | PPARA (0.53) | PPARAPPARDMRGPRX4FFAR4FFAR1 | |
| SCHEMBL3143308 | 0.83 | PPARA (0.55) | PPARAPPARDMRGPRX4FFAR4FFAR1 | |
| SCHEMBL10801456 | 0.83 | PPARA (0.52) | PPARAPPARDMRGPRX4FFAR4FFAR1 | |
| SCHEMBL4463869 | 0.83 | PPARA (0.52) | PPARAPPARDMRGPRX4FFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11154544-B2 | Amide derivatives as Nav1.7 and Nav1.8 blockers | RAQUALIA PHARMA INC. (JP) | 2021-10-26 | — | — | US | disclosed |
| EP-3487839-B1 | AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | RAQUALIA PHARMA INC (JP) | 2020-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11154544-B2 | Amide derivatives as Nav1.7 and Nav1.8 blockers | SCN8A, SCN7A, SCN1A | PPARA 2273/4885PPARD 2238/4885MRGPRX4 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.